Overture Life is focused on revolutionizing fertility treatments through innovative technologies that enhance assisted reproductive technology (ART) outcomes. Their flagship product, DaVitri, is an automated and portable embryology lab designed to streamline the processes involved in egg freezing and human reproduction. By integrating automation into these traditionally manual procedures, Overture Life aims to reduce costs and improve success rates in in vitro fertilization (IVF). The company recognizes that many barriers currently exist in ART, including a lack of consensus on best practices, which can lead to inconsistent and expensive treatments. 

In addition to DaVitri, Overture Life offers advanced solutions such as metabolomic profiling of embryos and automated Piezo ICSI (Intracytoplasmic Sperm Injection). These technologies are part of a broader vision to address the increasing demand for IVF by making the process more efficient and accessible. By harnessing automation, Overture Life seeks to transform the landscape of fertility treatment, ultimately making it more affordable and effective for millions of individuals seeking to conceive.

United States

Overture Life is a clinical-stage biotechnology company whose mission is to automate assisted reproductive processes to improve IVF pregnancy outcomes through process automation and non-invasive embryo selection. Its revolutionary technologies help standardize fertility treatments, by simplifying techniques and optimizing resources to make reproductive technologies more affordable, reliable, and accessible. Founded by recognized global leaders in embryo genetic testing and assisted reproduction, Overture is backed by Khosla Ventures, Felicis Ventures, Octopus Ventures and GV, and maintains offices in the U.S. and Spain.

Overture Life

Company Details